LAMIVUDINE and ZIDOVUDINE
- Product NDC
- 68071-4450
- 11-digit product format
- 680714450
- Labeler code
- 68071
- Product ID
- 68071-4450_d5931643-b080-22d0-e053-2995a90a43f9
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- LAMIVUDINE and ZIDOVUDINE
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- NuCare Pharmaceuticals,Inc.
- Application
- ANDA079124
- Marketing category
- ANDA
- Marketing start
- 2015-09-18
- Marketing end
- 0000-00-00
- Substance
- LAMIVUDINE; ZIDOVUDINE
- Active strength
- 150 mg/1; mg/1
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2023-12-31
- Current FDA listing
- Historical FDA.report record
FDA-Initiated Inactive NDC Indexing#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 68071-4450-6 | 68071445006 | 6 TABLET, FILM COATED in 1 BOTTLE (68071-4450-6) | 2018-05-25 | 0000-00-00 | No | No | Current |